close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

17.43 -0.07 (-0.43%)
Streaming Delayed Price Updated: 10:12 AM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader 
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients ↗
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by... 
Via Benzinga
News headline image
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
Newly created position to lead efforts focused on continued growth and sales 
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
9 Analysts Have This To Say About Legend Biotech ↗
 
Via Benzinga
News headline image
Where Legend Biotech Stands With Analysts ↗
 
Via Benzinga
News headline image
Peering Into Legend Biotech's Recent Short Interest ↗
 
Via Benzinga
News headline image
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma ↗
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
Via Investor's Business Daily
News headline image
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock ↗
 
Via Benzinga
News headline image
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Looking Into Legend Biotech's Recent Short Interest ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock ↗
 
Via Benzinga
News headline image
LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024 ↗
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
The Latest Analyst Ratings For Legend Biotech ↗
 
Via Benzinga
News headline image
Assessing Legend Biotech: Insights From 15 Financial Analysts ↗
 
Via Benzinga
News headline image
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation? ↗
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its... 
Via Benzinga
News headline image
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio? ↗
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your... 
Via Benzinga
News headline image
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal ↗
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal. 
Via Talk Markets
News headline image
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
CPI Data Sparks Rally in Biotech Stocks
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
Via MarketBeat
Topics ETFs Economy
News headline image
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients ↗
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of... 
Via Benzinga
News headline image
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis 
From Legend Biotech USA Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today